MUSE
20.10.2021 15:02:13 CEST | Business Wire | Press release
Interaxon Inc. (Muse® ), a leading consumer neurotechnology and meditation company, today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005215/en/
Alongside the launch of the updated Muse S headband, Interaxon is launching an intelligent new kind of EEG-powered sleep experience that is designed to help put you to sleep and guide you back to sleep if you’ve woken during the night.
Interaxon has been excited to offer this never-before-seen sleep intervention after building on their successful release of sleep content & EEG sleep tracking insights to support healthy sleep habits. A recent 2021 study led by Western University, Cambridge Brain Science, Hatch, and Interaxon that used Muse S EEG-sleep support technology showed a 20% improvement in the Pittsburgh Sleep Quality Index, relative to controls wanting to improve their sleep.
“For many of us, increasingly busy days translate into busy minds at night and restless sleep. While sleep tracking can be helpful to gain insights on trends and changes in your sleep quality, tracking your sleep doesn’t provide immediate relief when you need it most,” said Walter Greenleaf, Chief Science Officer at Interaxon (Muse®). “According to the CDC, more than a third of American adults are not getting enough sleep on a regular basis with less than seven hours per day.1 This innovative new solution can help users get the rest they need to improve their overall wellness with a non-pharmaceutical sleep aid.”
Digital Sleeping Pills (DSPs)
Muse Digital Sleeping Pills or DSPs are designed to help you through the wind-down process by responding to your brain’s rhythms and helping you disengage from your busy mind. Muse S detects the natural changes in your brain activity as you fall asleep and uses those changes to gently fade out your audio to cue your brain that it’s time for sleep. If you wake in the night, Muse S uses the same Smart-Fade technology to automatically fade in the DSP content to guide you back to sleep again.
Sleep content preferences can vary widely from person to person. Some people are looking for a more engaging story to keep their mind from getting stuck in ruminating thoughts, while others may find a story too exciting to fall asleep to and prefer a softer, guided meditation or ambient soundscape. Depending on what type of content helps you fall asleep best, you can select a variety of different DSP’s to help you on your journey including all-new:
- Original, Classic, and Adventure Sleep Stories that have a voice narration of some of your favorite childhood stories & a variety of new original stories
- Ambient Sleep Soundscapes that offer soothing ambient music and harmonized sounds without a voice narrative
- Biofeedback Sleep Soundscapes that offer nature sounds and music that respond to biofeedback without a voice narrative
- Guided Sleep Meditations that have a meditation teacher guide you through a relaxing sleep meditation
In addition to the advanced EEG technology that Muse® is known for, the all-new second-generation Muse® S has improved signal quality for increased accuracy and enhanced battery performance with up to 50% reduction in charging time. Additionally, improved fit for a wider range of head sizes has been achieved with the same comfortable, adjustable, and washable fabric band.
Pricing and Availability
Muse® S (Gen 2) is now available for $399.99 USD at www.choosemuse.com and will be available on Amazon North America starting in 2022. Both first and second-generation Muse® S headbands will have access to the new Digital Sleep Pill (DSP) features free of charge with Gen 1 users gaining access in December of 2021.
To unlock Biofeedback+ and unlimited access to 500+ meditations with new content released monthly, you can subscribe to the Muse Premium Subscription for $12.99 USD per month or $94.99 USD per year.
In addition to a rich content library of more than 500 meditations from renowned meditation teachers, unlock access to a variety of relaxation techniques, Go-to-Sleep soundscapes, and in-depth courses with step-by-step instructions, such as The Sleep Basics course by Dr. Shelby Harris, an expert in behavioral sleep medicine. Additionally, you’ll have access to Biofeedback+ which is designed to allow you to see how your brain and body responds to external content whether it be music in Spotify, Audiobooks, or meditations in Headspace.
Now available at www.choosemuse.com .
About Muse ® by Interaxon Inc. :
At Muse®, our team of neuroscientists, meditation teachers, and engineers based out of Toronto who develop state-of-the-art experiences using research-grade EEG technology. Our goal is to help individuals build a rewarding meditation practice and live healthier, happier, more connected lives through human-centered technology. Our award-winning neurofeedback devices, and premium content offering of guided meditations with responsive learning functionality, is designed to help users meditate by providing real-time audio feedback on their meditative state through the Muse® companion app. We make the intangible, tangible. Muse is headquartered in Toronto, Canada, and has subsidiaries in the U.S. and Ireland.
More information about Muse® is available at www.choosemuse.com .
Milestones we’re excited about:
- More than 500,000 Musers globally
- Accessible: Muse is available in four languages, including English, Spanish, French and German
- Sessions of meditation with Muse ®: Over 100 million minutes to date and currently one of the largest brain data (EEG) collections in the world.
- Research institutions using Muse®: The Mayo Clinic, NASA, Harvard, MIT, U of T, UCL, UCSD, Inria, UVic, UBC, and many more.
- Meditating with Muse® works: Muse has been used in over 200 published studies, including Mayo Clinic who demonstrated meditating with Muse increases quality of life, and decreases stress and fatigue in cancer patients.
- Untangle Podcast : With more than 7 million plays, Untangle hosts Patricia Karpas and Ariel Garten interview thought-provoking authors, experts and leaders in areas related to mindfulness, sleep, neuroscience, brain health practices, and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005215/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
